Defense Therapy Collaboration Agreement with Orano to Develop Next Generation Targeted Radioimmunotherapy for Cancer

Vancouver, British Columbia–(Newsfile Corp. – August 13, 2024) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immuno-oncology vaccines and drug delivery technologies, is pleased to provide an update on its partnership with Orano Support SAS in the field of radiopharmaceuticals., on behalf of Orano SAS (“Orano”), a world-renowned multinational nuclear company headquartered in France.

In collaboration with Orano Support SAS, the Ministry of Defence is developing a novel radioimmunoconjugate (“RIC”), which contains an antibody to deliver the radioactivity specifically to cancer cells, a chelating agent linked to the radionuclide and specific Defence accumulation.^® variants, resulting in greater efficacy to treat cancers. The goal of this project is to develop next-generation RIC that exploits the therapeutic dependence of Auger electron (“AE”) emitter elements in proximity to nuclear DNA in combination with Defense’s Accum^® technology to induce its nuclear accumulation. AE emitters are promising radionuclides for RIC development because of their very short path length radiation energy deposition, which reduces radiotoxicity to healthy tissue.

The Accum^® moiety can overcome important limitations of RIC, such as endosomal sequestration and poor nuclear accumulation, by disrupting the endosome membrane without affecting the plasma membrane or mAbs specificity and by forcing nuclear re-localization of the RIC. Defence has developed a variety of Accum® variants with different biochemical properties and activities, such as hydrophobicity and cytotoxicity.

Currently, no cancer treatment uses this type of radionuclides in RIC formulation due to the lack of efficacy caused by their endosomal entrapment and their dependence on being close to nuclear DNA. Defence’s goal is to treat cancers efficiently with the potential to open a new market for cancer therapy based on a very promising radiotherapy involving AE emitter radionuclides.

Defense has completed the conceptualization of the Accum^® variant peptides and secure their production/manufacturing. Defense has demonstrated and patented that some Accum^® variants can be conjugated to an antibody or antibody conjugate to deliver it to the nucleus. Defense is also pleased that they have the in vitro And in the flesh preclinical studies to be performed by the radiopharmaceutical science team at the Canadian nuclear laboratories.

Diskutieren Sie über die entaltenen Werte